ANTIBODY TITRE DEVELOPMENT FOLLOWING ACCELERATED AND STANDARD HEPATITIS B VACCINATION SCHEDULE
- Registration Number
- CTRI/2023/02/049966
- Lead Sponsor
- SCHOOL OF TROPICAL MEDICINE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Age more than 18 years and of all genders.
Hepatitis B vaccine naïve persons
People living with HIV attending out-patient department, ART centre
Family members of patients attending hepatitis clinic at school of tropical medicine.
People with known hepatitis B virus infection.
People with chronic kidney disease.
People with malignancy or on chemotherapy.
People with diagnosed autoimmune disease.
People with severe HIV infection (WHO stage 3 and stage 4 disease), with CD4 count less than 200.
People on steroids for more than 4 weeks or on any immunomodulator therapy.
People received immunoglobulin in last 3 months.
People having history of allergy to any vaccine or vaccine compound
People with age more than 60 years
Patients suffering from any acute illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To see development of immunogenicity i.e., Anti HBs antibody titre following classical hepatitis B vaccine schedule (0,1-month,6 month) and accelerated hepatitis B vaccine schedule (0, day 10, day 21)Timepoint: Anti HBs antibody titre will be done at baseline,2 month (only for accelerated schedule), 7 month following 1st dose of vaccine
- Secondary Outcome Measures
Name Time Method complianceTimepoint: accelerated schedule: at 2 month <br/ ><br>standard schedule: at 7 months